Zacks Investment Research upgraded shares of MacroGenics (NASDAQ:MGNX) from a sell rating to a hold rating in a research note published on Tuesday, February 13th.
According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “
MGNX has been the topic of a number of other reports. BidaskClub lowered shares of MacroGenics from a sell rating to a strong sell rating in a report on Thursday, December 14th. Cowen reissued a buy rating on shares of MacroGenics in a report on Wednesday, January 24th. SunTrust Banks restated a buy rating and set a $31.00 target price on shares of MacroGenics in a research report on Tuesday, January 23rd. ValuEngine downgraded shares of MacroGenics from a sell rating to a strong sell rating in a research report on Tuesday, November 14th. Finally, Raymond James Financial reiterated a buy rating on shares of MacroGenics in a research report on Monday, December 11th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $30.60.
In other news, SVP Jon Marc Wigginton sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Eric Blasius Risser sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $22.50, for a total transaction of $67,500.00. Following the completion of the transaction, the senior vice president now owns 12,100 shares in the company, valued at $272,250. The disclosure for this sale can be found here. Corporate insiders own 8.30% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Legal & General Group Plc raised its holdings in shares of MacroGenics by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 328 shares in the last quarter. Parametric Portfolio Associates LLC purchased a new position in shares of MacroGenics in the 2nd quarter valued at $203,000. Teacher Retirement System of Texas purchased a new position in shares of MacroGenics in the 4th quarter valued at $225,000. Virtu KCG Holdings LLC purchased a new position in MacroGenics during the 2nd quarter worth $232,000. Finally, MetLife Investment Advisors LLC purchased a new position in MacroGenics during the 4th quarter worth $281,000. Institutional investors and hedge funds own 85.30% of the company’s stock.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.